MN
MNKD
MANNKIND CORP
$3.66
-2.40%
$1.1B
No data for this timeframe.
Vol
Market Cap$1.1B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders50 funds
Inst. Value$302.2M
Inst. Activity18 buys / 12 sells
Insider Activity1B / 2S
Insider Net $$193.3K
Reddit Sentiment80° Bullish
SEC Reports6
Press Releases4
Recent Activity
Jul 26, 2026
fda_pdufa
PDUFA: MNKD — Furoscix ReadyFlow Autoinjector in IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) — 2026-07-26
FDA target action date 2026-07-26 for MNKD (MANNKIND CORP). Drug: Furoscix ReadyFlow Autoinjector. I
Jun 3, 2026
Press
MannKind announced completion of patient randomization in the U.S. Phase 1b INFLO-1 trial and enrollment of the first pa
Impact 5/10
Jun 2, 2026
SEC
MannKind announced FDA approval of Afrezza (insulin human) Inhalation Powder for pediatric use in children and adolescen
8-K — Impact 7/10
May 29, 2026
Press
MannKind received FDA approval for Afrezza® in children and adolescents aged 6+. This expands the addressable patient po
Impact 8/10
May 28, 2026
SEC
MannKind announced the FDA released it from a postmarketing requirement for Afrezza—a five-year pulmonary malignancy stu
8-K — Impact 6/10
May 20, 2026
Insider
Kay Sabrina was granted 82,781 shares
Director
May 20, 2026
Insider
MUNDKUR CHRISTINE was granted 82,781 shares
Director
May 20, 2026
Insider
Marasco Dominic was granted 8,474 shares
Pres, Endocrine Business Unit @ $2.95 ($25.0K)
Price Targets
$7.59
+107.5% upside
Strong Buy
Current $3.66
Low $4.75
Median $7.00
High $11.00
8 analysts
$4.75
$11.00
Analyst Ratings
4Strong Buy
8Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 7, 2026 | RBC Capital | MAINTAIN | Sector Perform → Sector Perform |
| May 7, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| May 7, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| May 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 28, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.01 ▼ -6.2% | $0.00 — $0.03 | -75% YoY | 4 |
| Next Q | $0.02 ▲ +100.0% | $0.01 — $0.05 | -71% YoY | 4 |
| Current FY | $0.09 ▼ -1.9% | $0.04 — $0.15 | -55% YoY | 4 |
| Next FY | $0.19 | $0.12 — $0.24 | 126% YoY | 4 |
Latest Reports
NEUTRAL
Press
5/10
MannKind announced completion of patient randomization in the U.S. Phase 1b INFLO-1 trial and enrollment of the first pa
Jun 3, 2026
BULLISH
8-K
7/10
MannKind announced FDA approval of Afrezza (insulin human) Inhalation Powder for pediatric use in children and adolescen
Jun 2, 2026
BULLISH
8-K
6/10
MannKind announced the FDA released it from a postmarketing requirement for Afrezza—a five-year pulmonary malignancy stu
May 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $70.1M | — |
| STATE STREET CORP | $45.8M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $31.6M | — |
| MORGAN STANLEY | $14.2M | ADD |
| DIMENSIONAL FUND ADVISORS LP | $12.1M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 20, 2026 | Kay Sabrina | A | $0.00 |
| May 20, 2026 | MUNDKUR CHRISTINE | A | $0.00 |
| May 20, 2026 | Marasco Dominic | A | $25.0K |
| May 20, 2026 | Tross Stuart | A | $100.0K |
| May 20, 2026 | Shannon James | A | $0.00 |
Reddit Sentiment
80°
Bullish
Bearish
Neutral
Bullish
50 institutional holders with $302.2M total value (123,003,931 shares) as of 2026-Q1. Top holders: BlackRock,, STATE, VANGUARD. Net buying activity: 18 institutions added/increased vs 12 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 28,600,998 | $70.1M | 23.2% | — |
| 2 | STATE STREET CORP | 18,683,483 | $45.8M | 15.1% | ADD +27.8% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 12,891,066 | $31.6M | 10.5% | — |
| 4 | MORGAN STANLEY | 5,793,147 | $14.2M | 4.7% | ADD +30.4% |
| 5 | DIMENSIONAL FUND ADVISORS LP | 4,953,295 | $12.1M | 4.0% | — |
| 6 | Rubric Capital Management LP | 3,620,413 | $8.9M | 2.9% | TRIM -51.6% |
| 7 | FMR LLC | 3,480,964 | $8.5M | 2.8% | — |
| 8 | BANK OF AMERICA CORP /DE/ | 3,383,677 | $8.3M | 2.7% | ADD +43.2% |
| 9 | WELLINGTON MANAGEMENT GROUP LLP | 3,283,179 | $8.0M | 2.7% | — |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3,171,824 | $7.8M | 2.6% | — |
| 11 | GOLDMAN SACHS GROUP INC | 2,942,320 | $7.2M | 2.4% | — |
| 12 | TWO SIGMA INVESTMENTS, LP | 2,895,874 | $7.1M | 2.3% | TRIM -40.9% |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,549,067 | $6.2M | 2.1% | — |
| 14 | Avoro Capital Advisors LLC | 2,200,000 | $5.4M | 1.8% | TRIM -50.5% |
| 15 | Nuveen, LLC | 2,164,715 | $5.3M | 1.8% | — |
| 16 | VANGUARD FIDUCIARY TRUST CO | 2,137,637 | $5.2M | 1.7% | — |
| 17 | RENAISSANCE TECHNOLOGIES LLC | 1,868,442 | $4.6M | 1.5% | DOUBLED +106.6% |
| 18 | MARSHALL WACE, LLP | 1,561,889 | $3.8M | 1.3% | DOUBLED +491.0% |
| 19 | Invesco Ltd. | 1,505,604 | $3.7M | 1.2% | — |
| 20 | Point72 Asset Management, L.P. | 1,249,177 | $3.1M | 1.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | ADD | 14,623,269 | 18,683,483 | +27.8% | $45.8M | 2026-Q1 |
| MORGAN STANLEY | ADD | 4,443,922 | 5,793,147 | +30.4% | $14.2M | 2026-Q1 |
| Rubric Capital Management LP | TRIM | 7,476,495 | 3,620,413 | -51.6% | $8.9M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 2,362,221 | 3,383,677 | +43.2% | $8.3M | 2026-Q1 |
| Avoro Capital Advisors LLC | TRIM | 4,444,444 | 2,200,000 | -50.5% | $5.4M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 264,293 | 1,561,889 | +491.0% | $3.8M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | DOUBLED | 405,660 | 1,232,078 | +203.7% | $3.0M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | ADD | 587,186 | 869,254 | +48.0% | $2.1M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 472,859 | 726,396 | +53.6% | $1.8M | 2026-Q1 |
| DEUTSCHE BANK AG\ | TRIM | 843,026 | 610,510 | -27.6% | $1.5M | 2026-Q1 |
| Rafferty Asset Management, LLC | ADD | 452,470 | 581,530 | +28.5% | $1.4M | 2026-Q1 |
| Freestone Grove Partners LP | DOUBLED | 14,137 | 231,802 | +1539.7% | $567.9K | 2026-Q1 |
| HSBC HOLDINGS PLC | DOUBLED | 71,068 | 212,038 | +198.4% | $508.9K | 2026-Q1 |
| TUDOR INVESTMENT CORP ET AL | DOUBLED | 32,108 | 156,828 | +388.4% | $384.2K | 2026-Q1 |
| KING LUTHER CAPITAL MANAGEMENT CORP | ADD | 102,995 | 138,605 | +34.6% | $339.6K | 2026-Q1 |
| Russell Investments Group, Ltd. | NEAR_EXIT | 578,402 | 127,860 | -77.9% | $313.3K | 2026-Q1 |
| ExodusPoint Capital Management, LP | TRIM | 245,279 | 112,855 | -54.0% | $276.5K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 200 | 77,627 | +38713.5% | $190.2K | 2026-Q1 |
| GROUP ONE TRADING LLC | ADD | 55,099 | 76,084 | +38.1% | $186.4K | 2026-Q1 |
| STIFEL FINANCIAL CORP | ADD | 54,740 | 70,976 | +29.7% | $173.9K | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | DOUBLED | 17,905 | 46,810 | +161.4% | $114.7K | 2026-Q1 |
| Concurrent Investment Advisors, LLC | TRIM | 26,000 | 19,223 | -26.1% | $47.1K | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | TRIM | 33,405 | 18,748 | -43.9% | $45.9K | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | TRIM | 23,962 | 17,338 | -27.6% | $42.5K | 2026-Q1 |
| Lido Advisors, LLC | ADD | 11,185 | 14,100 | +26.1% | $34.5K | 2026-Q1 |
15 unique insiders with 40 transactions. Net insider value: $193.3K ($259.0K bought, $65.7K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Kay Sabrina | Director | AWARD | 82,781 | — | — |
| May 20, 2026 | MUNDKUR CHRISTINE | Director | AWARD | 82,781 | — | — |
| May 20, 2026 | Marasco Dominic | Pres, Endocrine Business Unit | AWARD | 8,474 | $2.95 | $25.0K |
| May 20, 2026 | Tross Stuart A | Chief People & Workpl Officer | AWARD | 33,898 | $2.95 | $100.0K |
| May 20, 2026 | Shannon James Samuel | Director | AWARD | 82,781 | — | — |
| May 20, 2026 | HOOPER ANTHONY C | Director | AWARD | 82,781 | — | — |
| May 20, 2026 | Grancio Jennifer | Director | AWARD | 82,781 | — | — |
| May 20, 2026 | Binder Steven B. | Director | AWARD | 82,781 | — | — |
| May 20, 2026 | Consiglio Ronald J | Director | AWARD | 10,000 | $2.95 | $29.5K |
| May 20, 2026 | Consiglio Ronald J | Director | AWARD | 82,781 | — | — |
| May 20, 2026 | Friedman Michael A | Director | AWARD | 82,781 | — | — |
| May 12, 2026 | Binder Steven B. | Director | SELL | 16,940 | $3.29 | $55.7K |
| May 12, 2026 | Thomson David | EVP Genl Counsel & Secretary | SELL | 3,033 | $3.29 | $10.0K |
| May 11, 2026 | Tross Stuart A | Chief People & Workpl Officer | TAX W/H | 8,073 | $3.52 | $28.4K |
| May 11, 2026 | Castagna Michael | Chief Executive Officer | TAX W/H | 34,957 | $3.52 | $123.0K |
| May 11, 2026 | Binder Steven B. | Director | TAX W/H | 5,560 | $3.52 | $19.6K |
| May 11, 2026 | Thomson David | EVP Genl Counsel & Secretary | TAX W/H | 12,387 | $3.52 | $43.6K |
| Apr 22, 2026 | Prentiss Christopher B | Chief Financial Officer | TAX W/H | 12,267 | $2.74 | $33.6K |
| Mar 23, 2026 | Prentiss Christopher B | Chief Financial Officer | AWARD | 221,000 | — | — |
| Mar 23, 2026 | Singh Sanjay R | EVP Technical Operations | AWARD | 221,000 | — | — |
| Mar 23, 2026 | Ahuja Ajay | Chief Medical Officer | AWARD | 217,000 | — | — |
| Mar 23, 2026 | Tross Stuart A | Chief People & Workpl Officer | AWARD | 217,000 | — | — |
| Mar 23, 2026 | Ahuja Ajay | Chief Medical Officer | AWARD | 221,000 | — | — |
| Mar 23, 2026 | Singh Sanjay R | EVP Technical Operations | AWARD | 217,000 | — | — |
| Mar 23, 2026 | Tross Stuart A | Chief People & Workpl Officer | AWARD | 221,000 | — | — |
| Mar 23, 2026 | Thomson David | EVP Genl Counsel & Secretary | AWARD | 217,000 | — | — |
| Mar 23, 2026 | Castagna Michael | Chief Executive Officer | AWARD | 782,000 | — | — |
| Mar 23, 2026 | Thomson David | EVP Genl Counsel & Secretary | AWARD | 221,000 | — | — |
| Mar 23, 2026 | Prentiss Christopher B | Chief Financial Officer | AWARD | 217,000 | — | — |
| Mar 23, 2026 | Castagna Michael | Chief Executive Officer | AWARD | 796,000 | — | — |
| Mar 10, 2026 | Castagna Michael | Chief Executive Officer | BUY | 100,000 | $2.59 | $259.0K |
| Mar 1, 2026 | Shannon James Samuel | Director | AWARD | 12,000 | $3.27 | $39.2K |
| Mar 1, 2026 | HOOPER ANTHONY C | Director | AWARD | 35,000 | $3.27 | $114.5K |
| Mar 1, 2026 | Prentiss Christopher B | Chief Financial Officer | AWARD | 5,000 | $3.27 | $16.4K |
| Mar 1, 2026 | Castagna Michael | Chief Executive Officer | AWARD | 15,290 | $3.27 | $50.0K |
| Mar 1, 2026 | Tross Stuart A | Chief People & Workpl Officer | AWARD | 15,290 | $3.27 | $50.0K |
| Feb 26, 2026 | Binder Steven B. | Director | AWARD | 45,025 | — | — |
| Feb 26, 2026 | Thomson David | EVP Genl Counsel & Secretary | AWARD | 20,000 | — | — |
| Feb 26, 2026 | Tross Stuart A | Chief People & Workpl Officer | AWARD | 20,000 | — | — |
| Feb 26, 2026 | Castagna Michael | Chief Executive Officer | AWARD | 50,000 | — | — |
6 SEC filing reports analyzed. Sentiment: 3 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 5.8/10.
BULLISH
8-K
7/10
MannKind announced FDA approval of Afrezza (insulin human) Inhalation Powder for pediatric use in ch
Jun 2, 2026
BULLISH
8-K
6/10
MannKind announced the FDA released it from a postmarketing requirement for Afrezza—a five-year pulm
May 28, 2026
NEUTRAL
CLUSTER
3/10
Two insiders at MannKind Corp made open-market sales totaling $66K (0.007% of market cap) on May 12,
May 14, 2026
BEARISH
PRESS-RELEASE
8/10
MannKind reported Q1 2026 GAAP EPS of -$0.05, a 600% miss vs. consensus of $0.01, and revenue of $90
May 6, 2026
NEUTRAL
DEFA14A
3/10
MannKind Corp (MNKD) is holding its 2024 Annual Meeting, where shareholders will vote on the re-elec
Apr 7, 2026
BULLISH
8-K
8/10
MannKind reported strong fourth quarter and full year 2025 financial results, with Q4 revenue up 46%
Feb 26, 2026
NEUTRAL
5/10
MannKind announced completion of patient randomization in the U.S. Phase 1b INFLO-1 trial and enroll
Jun 3, 2026
BULLISH
8/10
MannKind received FDA approval for Afrezza® in children and adolescents aged 6+. This expands the ad
May 29, 2026
BULLISH
8/10
MannKind announced FDA approval of Afrezza (inhaled insulin) for pediatric patients aged 6+ with typ
May 29, 2026
BULLISH
7/10
MannKind announced nine poster presentations at ADA 2026 covering Afrezza data in pediatric efficacy
May 27, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 14 analysts: 4 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.59 mean target
+107.5% upside
Strong Buy (1.25)
$4.75 Low
$11.00 High
| Metric | Value |
|---|---|
| Current Price | $3.66 |
| Target Low | $4.75 |
| Target Mean | $7.59 |
| Target Median | $7.00 |
| Target High | $11.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.01 | $0.00 | $0.03 | -75.0% | -6.2% | — | $0.1B | 42.4% | 4 |
| Next Q 2026-09-30 |
$0.02 | $0.01 | $0.05 | -71.4% | +100.0% | 1↑ 2↓ | $0.1B | 46.1% | 4 |
| Current FY 2026-12-31 |
$0.09 | $0.04 | $0.15 | -55.3% | -1.9% | 1↑ 2↓ | $0.5B | 32.3% | 4 |
| Next FY 2027-12-31 |
$0.19 | $0.12 | $0.24 | 126.5% | -0.4% | 1↑ 3↓ | $0.5B | 12.8% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.013 | |
| 7d ago | $0.013 | |
| 30d ago | $0.013 | -0.001 |
| 60d ago | $0.017 | -0.004 |
| 90d ago | $0.017 | -0.004 |
5 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 7, 2026 | RBC Capital | MAINTAIN | Sector Perform | Sector Perform |
| May 7, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 7, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 28, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Apr 13, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 5, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Feb 27, 2026 | RBC Capital | DOWNGRADE | Outperform | Sector Perform |
| Feb 27, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Feb 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 5 | 8 | 2 | 0 | 0 | 87% | |
| Mar 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
80°
Bullish
Bearish
Neutral
Bullish
6 mentions
6 bullish
0 bearish
6 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 1, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Mannkind $MNKD upgraded to buy
▲ 1
💬 1
⚡ 0.5
MNKD Mannkind Corp
▲ 1
💬 1
⚡ 0.5
Jul 26, 2026
fda_pdufa
PDUFA: MNKD — Furoscix ReadyFlow Autoinjector in IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) — 2026-07-26
FDA target action date 2026-07-26 for MNKD (MANNKIND CORP). Drug: Furoscix ReadyFlow Autoinjector. Indication: IV-equivalent diuretic dose (subcutaneo
Jun 12, 2026
short_volume
Short Volume: MNKD — 61.6% short (1.1M / 1.8M)
Short: 1,085,782 | Exempt: 4,956 | TRF Vol: 1,763,378 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
other
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID
Jun 4, 2026
short_volume
Short Volume: MNKD — 56.7% short (1.0M / 1.7M)
Short: 964,440 | Exempt: 1,000 | TRF Vol: 1,701,518 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
fda
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INF
Jun 3, 2026
short_volume
Short Volume: MNKD — 58.6% short (0.8M / 1.4M)
Short: 813,348 | Exempt: 4,699 | TRF Vol: 1,387,473 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: MNKD — 64.3% short (1.4M / 2.2M)
Short: 1,391,831 | Exempt: 4,306 | TRF Vol: 2,163,288 | Short Ratio: 64.3% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: MNKD — 61.3% short (2.3M / 3.8M)
Short: 2,307,207 | Exempt: 33,395 | TRF Vol: 3,763,893 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
May 29, 2026
fda
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
<p align="left">DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- <strong>MannKind Corporation (Nasdaq: MNKD)</strong> a
May 29, 2026
fda
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
MannKind Announces FDA Approval of Afrezza® the 1st & Only Inhaled Mealtime Insulin for Use in Children & Adolescents
Aged 6 and Older Living with Dia
May 29, 2026
fda_pdufa
PDUFA: MNKD — Afrezza in pediatric — 2026-05-29
FDA target action date 2026-05-29 for MNKD (MANNKIND CORP). Drug: Afrezza. Indication: pediatric. PDUFA target action date for Afrezza pediatric indic
May 29, 2026
short_volume
Short Volume: MNKD — 66.0% short (5.8M / 8.8M)
Short: 5,824,419 | Exempt: 20,989 | TRF Vol: 8,819,733 | Short Ratio: 66.0% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: MNKD — 60.6% short (1.5M / 2.5M)
Short: 1,511,024 | Exempt: 3,482 | TRF Vol: 2,495,086 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
May 27, 2026
other
MannKind to Present at Jefferies Global Healthcare Conference
<p>DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- <strong>MannKind Corporation (Nasdaq: MNKD)</strong>, announced tod
May 27, 2026
fda
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
MANNKIND TO SHOWCASE NEW DATA AT ADA 2026 ADVANCING UNDERSTANDING OF INHALED INSULIN (AFREZZA®) IN PEDIATRIC CARE, PREGNANCY AND USE WITH AID SYSTEMS